Libraries of overlapping peptides or synthetic gene-scale proteomes have been used to accelerate vaccine discovery, evaluation, and development. The unbiased and structure-agnostic nature of these approaches allows for discovery of all possible epitopes a pathogen can express. Synthesizing overlapping peptides that represent the entire proteome, or using a method such as a Phage display system to generate a complete proteome library, allows for immediate translation of sequence to antigen candidates once a pathogen's genomic sequence is available. This approach does not suffer from the selection bias of using only well-characterized proteins and is more likely to identify cryptic or strain-specific epitopes not used in current subunit vaccines. Peptide libraries also enable the ability to rapidly screen antibody and T cell responses from diverse cohorts of donors using multiplexed immunoassays, accelerating the nomination, de-selection, and validation process. Additionally, peptide libraries can be used as surrogate antigens for high throughput screening of humoral and cellular immune responses in a BSL-1 environment, even when the native microbe may be a BSL-3 pathogen. Thus, industrial and academic laboratories can perform immune monitoring at scale without high-containment facilities. Peptide antigens identified in discovery can also be directly reformulated into a multi-epitope immunogen without extensive antigen redesign or engineering, reducing pre-clinical development timelines. Finally, because synthetic peptides are defined chemicals and lack adventitious agents, safety profiling can be performed earlier in development and regulatory concerns are reduced.
Fig. 1 Summary of workflows and assay methods of different T cell antigen discovery approaches.1,2
Peptide-based epitope mapping campaigns are typically grounded in the assumption that antigen/antibody or antigen/T-cell interactions are dictated by short contiguous or constructed motifs which are faithfully recapitulated in vitro. Exhaustive interrogation of overlapping or truncation fragments can then be used to focus recognition to the shortest string of residues required for binding (resolution sometimes approaching single amino acid) without requiring solution of tertiary structure. Alanine- or positional-scanning variants can be further screened to identify energetic hot-spots. Random or scrambled variants can then be used to identify degenerate specificity signatures which may be more robust to viral quasi-species variation. Critically, when displayed on phage, microbeads or microarrays, such libraries can be used to screen polyclonal sera, monoclonal antibodies, or even sorted T-cell populations in massively parallel fashion. Low-frequency specificities can be thus made quantifiable, and the resulting signals can be used in downstream vaccine design. The comprehensive epitope atlas generated in this way can then be used to select either conserved regions for inclusion in broadly protective vaccine formulations, or immunodominant sites that are associated with protective immunity (or immune-mediated enhancement) and thus drive candidate away from potentially deleterious targets. Because the same peptide reagents can be used as diagnostics, immune-monitoring tools, and in vaccine constructs, such mapping also simultaneously creates the reagents needed for later clinical validation, and thus collapses several traditionally separate phases of vaccine discovery into a single pipeline.
To truly reflect the antigenic universe of a pathogen, each and every reading frame, post-translational modification and strain must be included in the screen. Peptide libraries have been used to this effect, as they can tile entire proteomes at once with short overlapping peptides that sample both linear and conformational discontinuous determinants, including those present in internal loops but exposed at the surface due to conformational breathing. Chemically modified and non-proteinogenic amino acids can be included to represent known or hypothesized glycosylated, phosphorylated or citrullinated states that can be key to self vs. non-self discrimination in autoimmune or cancer antigens. Degenerate codons could be used to include all known or predicted variants in the peptide library without having to actually synthesize each mutant separately for targets such as pathogens that use hyper-mutation as an immune evasion strategy. These "cloud" libraries could thus account for quasispecies of an organism. By including each possibility in the library and using next generation sequencing of bound peptides, low abundance peptides can also be represented. The result is a comprehensive view of potential antigenic targets that is unattainable with candidate-based approaches. The end result is a set of epitopes that, when considered as a whole, reflect the entire antigenic landscape of a given pathogen. This should result in the most effective vaccines in terms of breadth and duration of protection in diverse populations.
A key feature of the next-generation peptide library platforms is that they have been designed to be used in a massively parallel format, allowing from tens to hundreds of thousands of sequences to be assayed in the same tube. The features of microscale solid-phase synthesis and microfluidic spotting, together with particle display by encoding, have led to a decrease in both reagent and sample use, while still allowing detection at femtomole levels for the binding assays. Quantitative analysis by multiparametric flow cytometry, bar-coded microarrays or deep sequencing based decoding, transform the readouts from qualitative to quantitative within hours, and allows for the establishment of affinity hierarchies, off-rate kinetics, and cross-reactivity profiles in place of the weeks previously required. The same screening procedures can be applied directly to polyclonal sera from multiple sources, to HLA-typed T-cell panels or antibody libraries from convalescent patients, which means that population diversity can be sampled in early discovery stages. The integration of robotic liquid handling with machine-learning-guided data analysis has made it possible to do rounds of enrichment and counter-screening iteratively, without manual intervention, and have reduced months of laboratory effort to days of unattended instrument runtime. This level of throughput not only speeds up the identification of candidates but also provides the statistically significant datasets for downstream in silico modeling and epitope prioritization as well as rational vaccine construction.
The best argument for the speed of peptide libraries is the accelerated timeline from genomic sequence to validated antigen on the order of weeks instead of years. Bioinformatic algorithms can automatically select preferred peptide lengths, offsets, and chemical modifications once a pathogen genome is made public overnight; then parallel synthesis technologies can convert these in silico designs into physical products on the order of days ready to be used as screening reagents without the lead time of culture or biosafety level constraints. Also, because the peptide probes are chemically pure and sequence-defined, orthogonal validation assays such as ELISpot, intracellular cytokine staining, or surface plasmon resonance can begin in parallel rather than serially, as opposed to the waterfall of antigen production, purification, quality control, and immunological testing. In addition, hits that work are themselves the end point of vaccine components—no further trimming, refolding, or carrier conjugation is strictly needed—so the same molecules that come out of discovery pipelines can go into formulation, toxicology, and GMP manufacturing without further design. The result is a discovery timeline in weeks, and the upshot is that peptide-centric approaches become the de facto first line of defense against emerging outbreaks while traditional platforms are still in upstream development stages.
Repeatedly in different pathogen systems, peptide-based discovery approaches have thus allowed fast conversion of sequence data into immunogens without need for culturing of whole pathogens. In the case of rapidly evolving RNA viruses, tiling arrays covering ORFs encoding structural and non-structural proteins were used to probe convalescent sera and identify cross-neutralising antibody signatures that were then translated into multivalent subunit vaccines. Similar efforts for more hyper-variable flaviviruses showed that in silico stitching of conserved peptide motifs into mosaic nanoparticles can induce long-term memory responses upon challenge in mouse and non-human primate models even when the library used to select the particles did not include the more variable surface loops. In chronic viruses such as hepatitis C, in contrast, pools of 15-mers spanning non-structural region NS3-NS5B helped to pinpoint the exquisite specificity of vaccine induced T cell populations and better understand why sterilising immunity is not achieved despite strong interferon-γ responses. In cancer, a similar principle was used to filter for peptide candidates with strict tumour specificity in silico followed by confirmation ex-vivo using patient peripheral blood to create epitope cocktails now entering adaptive therapy trials. Finally, also in the context of autoimmunity, peptide libraries have been used to identify the fine margins of self-tolerance, revealing that small post-translational modifications (as opposed to differences in primary sequence) can often distinguish pathogenic from innocuous epitopes. Taken together, these examples demonstrate how peptide based discovery approaches can blur the lines between exploratory immunology and pre-clinical development by providing a seamless path from epitope to formulation irrespective of the disease.
Using such synthetic peptide pools, designed to cover the entire proteome of a virus, one can screen for the optimal antigens for the development of vaccines that are therapeutically broad and effective on antigenically drifted populations. Overlapping peptides, that span all reading frames, recapitulate the antigenic repertoire of the pathogen during natural infection. These peptide pools are an unbiased representation of all peptides in a viral genome and can be used to represent high genetic diversity viruses, like RNA viruses, which have large numbers of virus quasi-species during an infection. In the case of RNA viruses, even minority viral quasi-species are present as overlapping peptide sequences in the pool. This approach also screens for potential epitopes that will be conserved as well as those which are hyper-variable. Peptide pools can be screened ex-vivo in large batches with PBMCs from multiple donor populations from multiple geographic locations. Potential hits are then sub-divided into different immunodominant and sub-dominant pools and rational down-selection of these peptide sequences is performed for vaccine candidates. These peptide sequences are then reformulated into stable nanoparticle or lipidated conjugate forms. The peptide reagents are then used as a standardized diagnostic for measuring antigen-specific recall responses during both pre-clinical and clinical trials, bypassing the need for handling replication-competent virus and eliminating a source of biosafety risk.
One of the first applications of peptide libraries in biomedicine is in cancer vaccine development. Peptide libraries are used to identify specific epitopes for T cell receptors from a mixture of different candidates. This approach has moved away from the more traditional methods of using whole cells as vaccines to a more tailored approach in epitope-guided vaccine design. Mining for epitopes can begin with in-silico prediction and ranking of candidate fragments, but with libraries one can extend this to in vitro testing on physical copies of all possible 8–25-mers, including post-translationally modified analogs such as phosphorylated or glycosylated peptides, that are often overexpressed in cancer cells. High throughput assays on patient T cell samples can then be performed in parallel against the thousands of peptides, identifying both the more traditional tumour associated antigens as well as patient-private neo-epitopes, a result of unique somatic mutations. These T cell screening assays can then be followed by positional scanning and alanine walking to pinpoint the shortest peptide that T cells can still recognise with high affinity, as well as to remove cross-reactive sequences that recognise important self antigens. As the same peptide libraries are used as both the discovery and the antigen source, this approach also enables the rapid synthesis of peptides to move directly into GMP synthesis and vaccine formulation, since no antigen refitting is necessary and stability in storage is guaranteed by the physical properties of the short synthetic peptides themselves. For this reason, peptide libraries have become a favored discovery platform for personalized cancer vaccines.
Peptide libraries have also helped to understand the molecular cause of autoimmune disease, by comparing self epitopes that are seen during tolerance induction with those that drive disease-causing inflammation. Libraries of all possible fragments of a given candidate auto-antigen, and post-translationally modified variants (for example citrullinated or deamidated versions) can be used to screen self-reactive T-cell lines cloned from the inflamed organ, helping to identify the subtle chemical changes that tip the balance from anergy to autoimmunity. By also including closely related microbial sequences in the same library, it is often possible to identify mimicry instances in which pathogen-derived peptides activate self-reactive lymphocytes, providing clues to the initiating event. Once the disease-causing epitope has been identified, successive truncation and single residue substitution can help identify the minimal chemical structure necessary to induce non-responsiveness, with the aim of then using a tolerogenic peptide version to re-induce tolerance to the endogenous auto-antigen, without inducing global immunosuppression. These reagents can then also be used as longitudinal biomarkers, to monitor the spreading or contraction of the epitope over time in response to therapy.
Compared to the culture-dependent or recombinant-protein workflows they replace, peptide libraries shift the entire vaccine discovery process from a serial, multi-step pipeline to a single, convergent process. The conventional approach is linear: grow pathogen, clone genes, express proteins, purify under aseptic conditions, redesign if mutations occur; all of these steps add biosafety requirements and batch-to-batch variability. By contrast, synthetic peptides are sequence-defined reagents that are contaminant-free, shelf-stable at room temperature, and can be readily reconstituted; no cold-chain infrastructure is needed, which is a boon for point-of-care delivery. They are also highly standardized; every member of a peptide library is chemically identical, so data are comparable between laboratories, between seasons, and between regions. And, since the minimal epitope identified by screening is the final drug substance itself, no further truncation, refolding or carrier conjugation is strictly necessary, so the path to toxicology and GMP manufacturing is direct. The sum of these process simplifications is a lower FTE count, a reduced facility size, and a lighter regulatory footprint, with the bonus of higher-resolution immunology. The result of these performance improvements is that, taken together, peptide libraries enable faster development timelines, improved epitope granularity, and dramatically lower overall costs, which redefines the cost of epidemic and orphan vaccines.
Arguably the most important feature of peptide libraries is the speed with which they accelerate the antigen discovery timeline. Days after genomic sequence release, in silico tools predict every open reading frame as a set of overlapping oligomers; synthesis platforms print these sequences overnight; and lyophilised pellets are ready for immune screening with no intervening cloning or fermentation steps. As peptides are a chemically defined antigen, affinity tags, refolding buffers, and endotoxin removal are not needed. Reconstitution in aqueous buffer is all it takes to yield screening-ready material. Parallel solid-phase synthesis also means that hundreds of candidate epitopes can be evaluated in 96- or 384-well screening formats, collapsing what were once back-to-back validation cycles into one multiplexed experiment. And since positive hits are themselves the final vaccine components, the customary hand-off from "research-grade" to "clinical-grade" antigen is largely symbolic—only scale-up and sterile filtration separate early discovery from pre-clinical formulation. The elapsed time from sequence release to first-in-animal immunogenicity readouts is thus measured in weeks rather than quarters, a pace that brings vaccine development timelines in line with the outbreak response clocks imposed by emerging pathogens.
Precision in epitope mapping refers to the capacity to attribute immune recognition to the shortest string of residues which confer both high-avidity binding and a functionally intact epitope; peptide libraries inherently offer this degree of resolution. Through overlying or truncation matrices, each positive fragment is iteratively shortened until single amino acid substitutions unmask energetic hot-spots and/or tolerance to natural polymorphism. Positional scanning, in which each residue is sequentially replaced with a sentinel amino acid, can also be used to determine the energetic contribution of side-chain chemistry without resolving 3D-structures. Libraries may be designed with relevant post-translational modifications (PTM) such as phosphorylation, glycosylation, citrullination which often differentiate self from non-self or wild-type from tumour-specific neo-epitopes, and as such capture biologically relevant specificities that would otherwise be missed by using recombinant proteins. Because each peptide is chemically identical, binding curves obtained with surface plasmon resonance or biolayer interferometry are devoid of avidity artefacts, which can affect the characterization of multivalent antigens, resulting in true kinetic constants and the ability to rationally optimise epitopes. The result is an epitope atlas which localises not just dominant targets but sub-dominant specificities which may be used to improve breadth, directly and without loss of fidelity into multi-epitope string design.
Several factors underpin this economic advantage, which together result in an unusually low input cost per discovery experiment, limited capital cost for screening campaigns, and high information density per peptide. Solid-phase synthesis protocols use only milligram quantities of reagents, but lyophilised product is stable at room temperature for years, avoiding cold-chain costs associated with protein antigens. Screening campaigns typically use only standard ELISA or flow-cytometry hardware, so there is no capital expenditure for bioreactors or GMP suites in the early stages of discovery. Since the same peptide reagent is used as discovery tool, diagnostic coating antigen, and ultimately active pharmaceutical ingredient, there is no cost penalty for "re-purposing" between development phases: the transition from research to clinic is simply a matter of scaling synthesis under quality-controlled conditions rather than re-engineering the molecule itself. Parallel synthesis amortises fixed costs over thousands of sequences, driving the per-epitope expense to historically low levels while simultaneously generating datasets large enough to meet increasingly stringent regulatory requirements for population-wide epitope coverage. Together, these factors help to invert the traditional cost curve: instead of expenditures increasing as candidates progress, peptide-based programmes experience declining marginal costs with each successive phase, and even vaccines aimed at small-market or orphan indications are made economically viable.
Peptide libraries provide broad coverage of potential epitopes, making them invaluable in accelerating vaccine development. By screening overlapping peptides, researchers can rapidly identify immunogenic regions and prioritize candidates. Our libraries are custom-designed to match specific antigens, pathogens, or tumor targets, ensuring maximum relevance and efficiency. Validated with analytical testing and immune assays, our peptide libraries support high-throughput research that saves time and resources while improving accuracy in vaccine discovery.
Products & Services:
Advantages:
Vaccine discovery requires speed and accuracy. Leverage our peptide libraries to shorten timelines and improve epitope identification for vaccine research.
1. What is a peptide library?
A set of peptides for epitope screening.
2. How do they help vaccines?
They identify immunogenic epitopes quickly.
3. Can libraries be customized?
Yes, fully tailored libraries are available.
4. Are they validated?
Yes, HPLC/MS and immune assays confirm quality.
References
